BACKGROUND: The T cell receptor (TCR) is an heterodimeric protein on the cell membrane of cytotoxic T cells (CTLs). In CTLs TCRs mediate the recognition of target cells through interaction with specific, MHC class I presented peptides. MATERIALS AND METHODS: As a model system to show proof of principle we chose the Jurkat/MA cell line and the HLA-A2.1 binding MAGE-3 derived peptide 271-279, as target specificity. RESULTS: We show that this cell line can be successfully transduced with the dicistronic retroviral vector (LZRS) containing cDNAs encoding for the complete alpha and beta chains of the selected TCR. Following retroviral transduction, Jurkat/MA cells do express the anti-MAGE-3 TCR on their membrane. The transduced TCR is functional as travoductants are successfully triggered, upon stimulation with T2 cells or MAGE-3+ melanoma cells loaded with the MAGE-3 peptide. CONCLUSION: We conclude that TCR gene transfer is possible and it represents a powerful therapeutic tool for the genetical modification of T calls of patients sullering from cancer.
BACKGROUND: The T cell receptor (TCR) is an heterodimeric protein on the cell membrane of cytotoxic T cells (CTLs). In CTLs TCRs mediate the recognition of target cells through interaction with specific, MHC class I presented peptides. MATERIALS AND METHODS: As a model system to show proof of principle we chose the Jurkat/MA cell line and the HLA-A2.1 binding MAGE-3 derived peptide 271-279, as target specificity. RESULTS: We show that this cell line can be successfully transduced with the dicistronic retroviral vector (LZRS) containing cDNAs encoding for the complete alpha and beta chains of the selected TCR. Following retroviral transduction, Jurkat/MA cells do express the anti-MAGE-3TCR on their membrane. The transduced TCR is functional as travoductants are successfully triggered, upon stimulation with T2 cells or MAGE-3+ melanoma cells loaded with the MAGE-3 peptide. CONCLUSION: We conclude that TCR gene transfer is possible and it represents a powerful therapeutic tool for the genetical modification of T calls of patients sullering from cancer.
Authors: Nina C Flerin; Huabiao Chen; Tynisha D Glover; Pedro A Lamothe; Jian Hua Zheng; Justin W Fang; Zaza M Ndhlovu; Evan W Newell; Mark M Davis; Bruce D Walker; Harris Goldstein Journal: J Virol Date: 2017-02-28 Impact factor: 5.103
Authors: Riyasat Ali; Jeffrey Babad; Antonia Follenzi; John A Gebe; Michael A Brehm; Gerald T Nepom; Leonard D Shultz; Dale L Greiner; Teresa P DiLorenzo Journal: Immunology Date: 2016-08 Impact factor: 7.397
Authors: Richard A Morgan; Mark E Dudley; Yik Y L Yu; Zhili Zheng; Paul F Robbins; Marc R Theoret; John R Wunderlich; Marybeth S Hughes; Nicholas P Restifo; Steven A Rosenberg Journal: J Immunol Date: 2003-09-15 Impact factor: 5.422
Authors: J Babad; G Mukherjee; A Follenzi; R Ali; B O Roep; L D Shultz; P Santamaria; O O Yang; H Goldstein; D L Greiner; T P DiLorenzo Journal: Clin Exp Immunol Date: 2015-03 Impact factor: 4.330
Authors: Eugene V Barsov; Matthew T Trivett; Jacob T Minang; Haosi Sun; Claes Ohlen; David E Ott Journal: PLoS One Date: 2011-08-23 Impact factor: 3.240
Authors: Sarah A Overall; Jugmohit S Toor; Stephanie Hao; Mark Yarmarkovich; Giora I Morozov; Son Nguyen; Alberto Sada Japp; Nicolas Gonzalez; Danai Moschidi; Michael R Betts; John M Maris; Peter Smibert; Nikolaos G Sgourakis Journal: Nat Commun Date: 2020-04-20 Impact factor: 14.919
Authors: Mirjam H M Heemskerk; Manja Hoogeboom; Renate Hagedoorn; Michel G D Kester; Roel Willemze; J H Frederik Falkenburg Journal: J Exp Med Date: 2004-03-29 Impact factor: 14.307